Diabetic Nephropathy Treatment

A new drug has been developed to treat Diabetic Nephropathy. It can lower proteinuria and protect kidney function. Now go on reading to learn more information.

Kidney Treatment Group Invite Links

Alternative Therapy to help you fight against kidney disease.

Click sentence, you will see our therapeutic effect.

New Treatment for Diabetic Nephropathy

2019-04-15 16:57

New Treatment for Diabetic NephropathyGood news. A new drug has been developed to treat Diabetic Nephropathy. It can lower proteinuria and protect kidney function. Now go on reading to learn more information.

Diabetic Nephropathy is a typical secondary kidney disease. Long-term uncontrolled blood sugar is the "fuse" of kidney damage. But not all patients with diabetic nephropathy will have renal failure. Relatively speaking, kidney disease prefers diabetics who have a history of diabetes for more than 10 years and have poor blood sugar control for long-term.

Dangers of Diabetic Nephropathy

When glomeruli are damaged in early stage, most patients have microalbuminuria, which is a typical symptom of Diabetic Nephropathy. With the deterioration of renal function, some patients will have massive albuminuria, which can accelerate renal function sclerosis. In the most serious case, uremia occurs.

According to statistics, diabetic nephropathy has become the first cause of uremia, and also an important factor leading to the rapid growth of uremia patients. Faced with such a situation, whether diabetic patients or patients with diabetic nephropathy, are very looking forward to more effective drugs or treatment methods developed as soon as possible.

A new drug for diabetic nephropathy came into being at the historic moment.

Albuminuria is an important indicator of threatening renal function and has a far-reaching impact on the cure of diabetic nephropathy. At present, the drugs used to treat albuminuria for Diabetic Nephropathy patients are mainly antihypertensive drugs such as ARBs and ACEI, but not for patients with renal insufficiency.

Imarikiren, a new renin inhibitor, may solve these problems.

Imarikiren is an oral renin inhibitor with a bioavailability of 77% in humans

Sadayoshi Ito's team previously conducted a two-stage, multi-center, double-blind, placebo-controlled trial of 415 type 2 diabetic microalbuminuria patients aged 20-75 years. Studies have confirmed that imarikiren is more effective and safer in the treatment of microalbuminuria caused by diabetic nephropathy, and also has the effect of delaying the function of Diabetic Nephropathy.

The subjects of study were:

Patients aged between 20 and 75 years old, without hyperkalemia, malignant hypertension, cardiovascular disease, liver disease, and have been treated with ACE inhibitors, ARB or direct renin inhibitors.

The doses were divided into four categories:

Imarikiren 5 mg, 20 mg, 40 mg, 80 mg; placebo or candesartan 8 mg for 12 weeks.

The results are as follows:

1. Urinary albumin and creatinine decreased significantly, and the cure rate of microalbumin was high.

Urinary albumin creatinine ratio is also an important indicator of proteinuria and renal function, which can replace microalbuminuria.

The results showed that the urinary albumin/creatinine radio decreased in all the patients taking imarikiren at different doses: 16% of decrease in imarikiren 5 mg group, 27% in imarikiren 20 mg group, 38% in imarikiren 40 mg group, 39% in imarikiren 80 mg group and 31% in candesartan ester 8 mg group. Compared with placebo group, the urinary albumin/creatinine ratio in imarikiren group decreased significantly (P < 0.001).

In addition, at the end of the treatment, the albuminuria remission rate was higher in the four groups of patients taking imarikiren, reaching 25% in the 80 mg group and 0% in the placebo group.

Simply put, the decrease of urinary albumin creatinine ratio is more obvious in patients taking imarikiren, and the probability of microalbuminuria alleviating is higher, which is more conducive to delaying the development of renal function and reducing the risk of uremia.

2. Safety and good tolerance

Comparatively speaking, the risk of side effects or adverse effects in patients taking imarikiren increases with the increase of dosage. Most of the risks are mild to moderate, and the safety and tolerance are relatively good. However, further research is needed to avoid the adverse effects.

I believe that in the near future, diabetic nephropathy patients will be able to see imarikiren drugs, and look forward to it together! Currently, you can try systemic Chinese medicine treatment, which can help you improve renal function. For more information on Diabetic Nephropathy treatment, please leave a message below or contact online doctor.

As for you own illness conditions, you can get some guidance related to diet, exercise, medicines or some natural remedies. The online consultation service is free. Please remember to leave your email address, or phone number so that we can contact you and help you!
Please leave the patient's FULL name in case of a duplicate, and to make our doctor give timely response and help.

Full Name:








Phone Number:


Our Treatment Effect

Mouse over the picture, it can be magnified.

You can take a look at this patient's report. His creatinine was 1028 and urea level was 39.7 on 2018-12-11; creatinine level was reduced to 331 and urea was 16.1 on 2019-1-5. After about 25 days' treatment in our hospital, his creatinine level was reduced by 697, and urea was reduced by 23.6. Hope his condition gets better and better.

Say goodbye to dialysis

Our Treatment effect

Proteinuria is a common symptom of kidney disease

Mouse over the picture, it can be magnified.

It can make your urine foamy. Although it does not make you feel uncomfortable, it can impair your renal function and make your kidney disease worse. Conventional treatment such as steroids and immunosuppressants can hardly make it negative. In our hospital, systemic Chinese medicine treatment can help you turn it negative. Look at this picture, bubbles in urine become less and less with our treatment going on.